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Aim To compare the performance of several simple, non-
invasive models comprising various serum markers in di-
agnosing significant liver fibrosis in the same sample of 
patients with chronic hepatitis B (CHB) with the same judg-
ment standard.
Methods A total of 308 patients with CHB who had un-
dergone liver biopsy, laboratory tests, and liver stiffness 
measurement (LSM) at the Southwest Hospital, Chongq-
ing, China between March 2010 and April 2014 were retro-
spectively studied. Receiver operating characteristic (ROC) 
curves and area under ROC curves (AUROCs) were used to 
analyze the results of the models, which incorporated age-
platelet (PLT) index (API model), aspartate transaminase 
(AST) to alanine aminotransferase (ALT) ratio (AAR model), 
AST to PLT ratio index (APRI model), γ-glutamyl transpepti-
dase (GGT) to PLT ratio index (GPRI model), GGT-PLT-albu-
min index (S index model), age-AST-PLT-ALT index (FIB-4 
model), and age-AST-PLT-ALT-international normalized ra-
tio index (Fibro-Q model).
Results The AUROCs of the S index, GPRI, FIB-4, APRI, API, 
Fibro-Q, AAR, and LSM for predicting significant liver fibro-
sis were 0.726 (P < 0.001), 0.726 (P < 0.001), 0.621 (P = 0.001), 
0.619 (P = 0.001), 0.580 (P = 0.033), 0.569 (P = 0.066), 0.495 
(P = 0.886), and 0.757 (P < 0.001), respectively. The S index 
and GPRI had the highest correlation with histopatho-
logical scores (r = 0.373, P < 0.001; r = 0.372, P < 0.001, re-
spectively) and LSM values (r = 0.516, P < 0.001; r = 0.513, 
P < 0.001, respectively). When LSM was combined with S 
index and GPRI, the AUROCs were 0.753 (P < 0.001) and 
0.746 (P < 0.001), respectively.
Conclusion S index and GPRI had the best diagnostic per-
formance for significant liver fibrosis and were robust pre-
dictors of significant liver fibrosis in patients with CHB for 
whom transient elastography was unavailable.
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Liver fibrosis is a common pathological process in various 
chronic liver diseases, including chronic hepatitis B (CHB). 
In patients with CHB, early detection of liver fibrosis is cru-
cial for therapy planning and prognosis estimation. In par-
ticular, the presence of significant liver fibrosis is a strong 
indication for initiating antiviral therapy (1,2). However, liver 
biopsies, the gold standard for staging fibrosis, are not per-
formed in all hospitals (especially in primary care) because 
of their invasiveness, sampling errors, and complications. In 
addition, biopsies are not appropriate for monitoring dis-
ease progression. Transient elastography (FibroScan; Echo-
sens, Paris, France), which measures liver stiffness, is increas-
ingly being recognized as an excellent tool for assessing the 
degree of fibrosis (3,4). FibroScan’s noninvasive nature, re-
producibility, and diagnostic performance have also made 
it increasingly popular. However, not all hospitals have the 
means to purchase such expensive equipment.
Accordingly, in recent years combinations of serum biomark-
ers of liver fibrosis have been a hot research topic. Several 
serological models for liver fibrosis (5-7) that incorporate di-
rect or indirect biomarkers have been developed as alterna-
tives to biopsy. These models reportedly vary considerably 
in their ability to diagnose fibrosis, and their results are con-
flicting (8,9). The present study assessed the effectiveness of 
the following seven fibrosis models, all of which comprise 
routine serum biomarkers and were found to have predic-
tive value for significant liver fibrosis: age-platelet (PLT) in-
dex (API) (10), aspartate transaminase (AST) to alanine ami-
notransferase (ALT) ratio (AAR) (10,11), AST to PLT ratio index 
(APRI) (10,11), γ-glutamyl transpeptidase (GGT) to PLT ratio 
index (GPRI) (11), GGT-PLT-albumin (ALB) index (S index) (12), 
age-AST-PLT-ALT index (FIB-4) (13), and age-AST-PLT-ALT-in-
ternational normalized ratio (INR) index (Fibro-Q) (14).
MetHoDs
Baseline patients’ characteristics
This retrospective study included 308 consecutive patients 
with CHB attending the Department of Infectious Diseas-
es, Southwest Hospital, Chongqing, China between March 
2010 and April 2014. The criterion for diagnosis of CHB was 
serum hepatitis B surface antigen positive for more than 6 
months (2). All enrolled patients underwent liver biopsy, Fi-
broScan, and laboratory tests within 2 days of one another. 
Because liver stiffness measurement (LSM) values can be 
influenced by inflammation (15,16), patients with serum 
ALT concentrations more than five times higher than the 
upper limit of normal (42 IU/L in both sexes) were exclud-
ed. We also excluded patients with concurrent infection 
with other viruses, decompensated cirrhosis, hepatocellu-
lar carcinoma, hepatic failure, and other liver diseases. The 
research was conducted in accordance with the ethical 
guidelines of the Declaration of Helsinki 2008 and was ap-
proved by the ethics committee of our hospital. Each pa-
tient gave their written informed consent.
Liver biopsy
Ultrasonography-guided percutaneous liver biopsy was per-
formed using a 16 G disposable needle (Hepafix, B. Braun, 
Melsungen, Germany) under local anesthesia. Specimens of 
minimum length 10 mm were immediately fixed in 10% for-
malin for further analysis (17,18). All biopsy samples were re-
viewed independently by two histopathologists who were 
blinded to the clinical data. If they failed to reach an agree-
ment, a third histopathologist reviewed the material.
Liver fibrosis was classified into five stages according to the 
METAVIR scoring system as follows (19): F0, no fibrosis; F1, 
mild fibrosis without fibrous septum; F2, fibrosis with a few 
fibrous septa; F3, numerous septa without cirrhosis; and 
F4, cirrhosis. Significant liver fibrosis was defined as F2 or 
greater (F≥2) (1).
Fibroscan
LSM values were obtained with FibroScan by an experi-
enced operator (more than 40 000 measurements). The ex-




AAR AST (IU/L)/ALT (IU/L)
GPRI GGT (IU/L)/PLT (IU/L)
S index 1000 × GGT (IU/L)/(PLT (109/L) × ALB2 (g/L))
APRI (AST (IU/L)/ULN (IU/L)/PLT (109/L)) × 100
FIB-4 (age (years) × AST (IU/L))/(PLT (109/L) × ALT1/2 (IU/L))
Fibro-Q (10 × age (years) × AST (IU/L) × INR)/(PLT (109/L) × ALT 
(IU/L))
API Age (years): ≤30 = 0, 31-40 = 1, 41-50 = 2, 51-60 = 3, 61-
70 = 4, >70 = 5
PLT count ( × 109/L):
≥225 = 0, 200-224 = 1, 175-199 = 2, 150-174 = 3, 125-
149 = 4, <125 = 5
API is the sum of age and platelet count (possible value 
0-10)
*aaR – ast to aLt ratio; aLB – albumin; aLt – alanine aminotrans-
ferase; aPI – age-PLt index; aPRI – ast to PLt ratio index; ast – aspar-
tate transaminase; FIB-4 – age-ast-PLt-aLt index; Fibro-Q – age-ast-
INR-PLt-aLt index; GGt – γ-glutamyl transpeptidase; GPRI – GGt to 
PLt ratio index; INR – international normalized ratio; PLt – platelet; s 
index – GGt-PLt-aLB index; ULN – upper limit of normal.
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aminations were performed in accordance with the user 
manuals and steps described previously (15,20). LSM val-
ues are expressed as kilopascals (kPa). When the success 
rate (number of valid acquisitions divided by number of at-
tempts) was over 60% and the ratio of interquartile range 
to median under 30%, a median value of 10 successful 
measurements was considered valid.
Laboratory procedures
Fasting blood serum samples were used for laboratory 
tests. Serologies for hepatitis B surface antigen were de-
tected with an automated blood analyzer (Advia-Bayer, 
Leverkusen, Germany). Routine blood (measured by XT-
2000i, Sysmex, Kobe, Japan) and biochemistry variables 
(measured by 7600 Series, Hitachi, Tokyo, Japan) were as-
sessed, including PLT count, serum ALT, AST, GGT, ALB, total 
bilirubin (TBIL), alkaline phosphatase (ALP), and globulin 
concentrations. Using the formulas shown in Table 1, the 
API (10), AAR (10,11), APRI (10,11), GPRI (11), S index (12), 
FIB-4 (13), and Fibro-Q (14) were calculated, all of these be-
ing considered noninvasive models for evaluating the de-
gree of liver fibrosis.
statistical analysis
Baseline patients’ characteristics are presented as 
mean ± standard deviation or median (interquartile range), 
and categorical variables as number (percentage). Statisti-
cal analyses were carried out using SPSS v. 18.0 software 
(SPSS Inc., Chicago, IL, USA) and STATA statistical package 
(release 11, 1, 2010, Stata Corporation, College Station, TX, 
USA). Normality of distribution was assessed using the Kol-
mogorov-Smirnov test. Univariate analysis (t-test or Mann-
Whitney test as appropriate) was carried out to identify 
variables that differed significantly between patients with 
and without significant fibrosis. Correlations were calculat-
ed using Spearman test. Combined models were obtained 
by logistic regression. A value of P < 0.05 was considered 
statistically significant. The performance of the serological 
models was evaluated by their specificity and sensitivity 
as well as the area under receiver operating characteristic 
(ROC) curves. Cut-off values were determined according to 
the Youden index (21).
ResULts
Forty-six patients were excluded from the study for the fol-
lowing reasons: 16 patients had invalid LSM values because 
of low success rates or high interquartile ranges, 5 had con-
sumed >40 g/d of alcohol for at least 10 years, 5 had hepa-
titis C virus or hepatitis E virus coinfection, 8 had hepatocel-
lular carcinoma, and 12 had exacerbations of hepatitis. The 
remaining 262 patients were enrolled (Table 2).
The majority of the 262 eligible patients were male (198, 
75.6%) and middle-aged (35.8 ± 10.9 years), with a mean 
body mass index (BMI) of 22.9. The distribution of each fi-
brosis stage was as follows: F0, 77 (29.38%) patients; F1, 94 
(35.88%); F2, 51 (19.47%); F3, 19 (7.25%); and F4, 21 (8.02%). 
Therefore, 91 patients (34.73%) had significant liver fibro-
sis (F2-F4). Patients with non-significant fibrosis (F0-F1) and 
taBLe 2. Baseline characteristics of patients with chronic hepatitis B*†
Characteristics, median (IQR) total F0-F1 F2-F4 statistic P value
Male (n, %) 198/262 (75.6) 126/171 (73.4) 72/91 (79.1) t = 0.97 0.330
Age (year), mean ±SD  35.8 ± 10.9  35.8 ± 11.0 35.8 ± 10.6 t = 0.02 0.925
BMI (kg/m2), mean ±SD 22.9 ± 3.3  23.0 ± 3.8 22.6 ± 2.4 t = 5.9 0.766
PLT (109/L) 114 (90-155) 125 (93-165) 97 (86-141) Z = 3.2 0.001
AST (IU/L)  37 (27-49)  33 (26-44) 41 (32-56) Z = 3.6 <0.001
ALT (IU/L)  48 (32-68)  44 (31-66) 57 (36-75) Z = 2.8 0.009
GGT (IU/L)  29 (19-55)  25 (16-41) 49 (24-82) Z = 5.3 <0.001
ALP (IU/L)  74 (62-95)  72 (61-90) 80 (64-103) Z = 2.1 0.046
Globulin (g/L), mean ±SD  29.5 ± 4.4  29.4 ± 4.3 29.5 ± 4.7 t = 1.1 0.768
ALB (g/L), mean ±SD  44.3 ± 5.7  45.0 ± 4.8 42.9 ± 7.0 t = 10.4 0.008
TBIL (μmol/L)  14 (11-20)  13.8 (10.7-18.2) 15.4 (11.0-26.1) Z = 1.8 0.099
INR   0.93 (0.88-1.06)   0.91 (0.86-1.00)  1.01 (0.91-1.11) Z = 4.3 <0.001
LSM (kPa)   7.8 (5.6-11.7)   6.5 (4.9-8.9)  7.1 (7.1-16.9) Z = 6.2 <0.001
*aLB – albumin; aLt – alanine aminotransferase; aLP – alkaline phosphatase; ast – aspartate aminotransferase; BMI – body mass index; GGt – 
γ-glutamyl transpeptidase; LsM – liver stiffness measurement; PLt – platelet count; tBIL – total bilirubin; sD – standard deviation; INR – international 
normalized ratio; IQR – interquartile range.
†statistics and P values were calculated between patients with liver fibrosis F0-F1 and those with F2-F4.
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those with significant fibrosis (F2-F4) had no significant dif-
ferences in baseline characteristics, including sex, age, BMI, 
globulin, and TBIL (all P > 0.05); but they had significant dif-
ferences in other assessed variables, including ALT, AST, 
ALB, GGT, PLT, ALP, INR, and LSM (all P < 0.05).
Correlations of serum models with histological finding 
and LsM values
S index and GPRI had the highest correlations (r = 0.373, 
P < 0.001; r = 0.372, P < 0.001, respectively), FIB-4, APRI, and 
API had moderate correlations (r = 0.199, P = 0.001; r = 0.197, 
P = 0.001; r = 0.134, P = 0.030; respectively), and Fibro-Q and 
AAR had no correlation with histological finding of fibro-
sis stage (r = 0.133, P = 0.066; r = 0.01, P = 0.886; respective-
ly). Correlation coefficients of S index, GPRI, FIB-4, APRI, API, 
Fibro-Q, and AAR with LSM values were 0.516 (P < 0.001), 
0.513 (P < 0.001), 0.195 (P = 0.005), 0.167 (P = 0.015), 0.009 
(P = 0.897), and −0.011 (P = 0.874), respectively.
Performance of serum models in diagnosing significant 
liver fibrosis
AUROCs of S index, GPRI, FIB-4, APRI, API, Fibro-Q, and AAR 
for predicting significant liver fibrosis were 0.726, 0.726, 
0.621, 0.619, 0.580, 0.569 and 0.495, respectively (Figure 1 
and Table 3). Univariate logistic regression model showed 
that LSM values (odds ratio [OR] 1.173, 95% CI 1.099-1.252, 
P < 0.001), GPRI (OR 1.551, 95% CI 1.045-2.303, P = 0.029), 
and S index (OR 1.603, 95% CI 0.960-2.677, P = 0.071) best 
predicted significant liver fibrosis in patients with CHB 
(Table 4). Because of their good diagnostic performance, 
LSM values, S index, and GPRI were subjected to further 
analysis. According to the maximum Youden index, opti-
mal cut-off values of LSM, S index, and GPRI for predicting 
significant liver fibrosis were 10.7, 0.1369, and 0.2181, re-
spectively (Table 5).
Performance of combined models in diagnosing 
significant fibrosis
When the three most valuable models (LSM with S index 
or GPRI) were combined, the AUROCs for predicting signifi-
cant liver fibrosis were 0.753 (P < 0.001) and 0.746 (P < 0.001), 
with sensitivities of 78.5% and 77.2%, respectively. A com-
bination of either of these two models with LSM (S index 
+ LSM, GPRI + LSM) improved the performance to a better 
level than that achieved by the S index or GPRI alone (AU-
ROCs: 0.753 vs 0.726, 0.746 vs 0.726, respectively) (Figure 
2). However, the diagnostic performance of these combi-
nations was not significantly better than that of LSM (AU-
ROCs: 0.753 vs 0.757, 0.746 vs 0.757, respectively).




(95% confidence interval) P value
LSM 1.173 (1.099-1.252) <0.001
S index 1.603 (0.960-2.677) 0.071
GPRI 1.551 (1.045-2.303) 0.029
FIB-4 1.054 (0.937-1.186) 0.379
APRI 1.002 (0.935-1.074) 0.954
API 1.145 (0.994-1.145) 0.060
Fibro-Q 0.999 (0.995-1.003) 0.662
AAR 0.750 (0.463-1.214) 0.242
taBLe 5. optimal cut-off values of models in diagnosing significant liver fibrosis*
Models Cut-off values specificity (%) sensitivity (%) Youden index† NLR PLR NPV (%) PPV (%)
LSM 10.7 85.5 53.2 0.387 0.548 3.666 75.2 68.9
S index  0.1841 77.65 59.78 0.374 0.518 2.675 77.65 57.61
GPRI  0.2343 58.24 79.35 0.376 0.355 1.899 83.19 48.95
*aPRI – aspartate transaminase (ast) to platelet (PLt) ratio index; FIB-4 – age-ast-PLt-alanine aminotransferase (aLt) index; GPRI – γ-glutamyl trans-
peptidase (GGt) to PLt ratio index; NLR – negative likelihood ratio; NPV – negative predictive value; PLR – positive likelihood ratio; PPV – positive 
predictive value; s index – GGt -PLt-albumin index.
†max (sensitivity + specificity −1).
taBLe 3. Diagnostic performance of liver fibrosis models*
standard P 95% confidence interval
Models aURoC error value Lower bound Upper bound
LSM 0.757 0.034 <0.001 0.690 0.823
S index 0.726 0.033 <0.001 0.662 0.791
GPRI 0.726 0.032 <0.001 0.662 0.789
FIB-4 0.621 0.037 0.001 0.549 0.692
APRI 0.619 0.035 0.001 0.550 0.688
API 0.580 0.037 0.033 0.508 0.652
Fibro-Q 0.569 0.037 0.066 0.496 0.642
AAR 0.495 0.037 0.886 0.421 0.568
*aaR – aspartate transaminase (ast) to alanine aminotransferase 
(aLt) ratio; aPI – age-platelet (PLt) index; aPRI – ast to PLt ratio in-
dex; aURoC – area under the receiver operating characteristic curve; 
FIB-4 – age-ast-PLt-aLt index; Fibro-Q – age-ast- international 
normalized ratio (INR)-PLt-aLt index; LsM – liver stiffness measure-
ment; GPRI – γ-glutamyl transpeptidase (GGt) to PLt ratio index; s 
index – GGt-PLt -albumin index.
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DIsCUssIoN
Our study showed that S index and GPRI had the best di-
agnostic accuracy performance for significant liver fibrosis 
and were robust serum prediction models of significant 
liver fibrosis in patients with CHB. Liver fibrosis is consid-
ered a regenerative response to liver injury caused by 
increased production and decreased destruction of 
the extracellular matrix. In patients with CHB, a pathologi-
cal finding of significant liver fibrosis indicates the need for 
immediate treatment. The major models of evaluating liver 
fibrosis in patients with CHB are liver biopsy, FibroScan, and 
serum biomarkers, the latter being more frequently avail-
able in primary care settings than the other two.
Dozens of serum liver fibrosis models have been devel-
oped and validated in clinical practice, all of them noninva-
sive, low-cost, and with AUROCs 0.50 ~ 0.86 (10). However, 
some serum models include biomarkers that are not rou-
tinely available, such as haptoglobin in Fibrotest (22) and 
α2-macroglobulin in Fibroscore (23), which is why many 
hospitals do not perform them. Furthermore, these mod-
els entail greater financial cost. In this study, we selected 
seven fibrosis models that include only routine laborato-
ry test and are easily calculated. Also, most of them have 
frequently been used to assess liver fibrosis in patients 
with chronic hepatitis C (CHC). Because CHC and CHB dif-
fer greatly in terms of the histological changes in the liv-
er and mechanisms that trigger fibrosis (6), models used 
in patients with CHC should be validated in CHB patients. 
We compared the predictive value of these seven models 
in the same sample of patients with the same judgment 
standard.
The highest performance for differentiating significant fi-
brosis in patients with CHB was found for LSM, followed 
by S index, GPRI, APRI, and FIB-4. On the other hand, API, 
Fibro-Q, and AAR showed poor or no predictive value. 
Logistic regression analysis showed that LSM values and 
GPRI were predictors of significant liver fibrosis. It should 
be noted that the S index (P value of odds ratio 0.071) 
was a borderline significant factor, meaning that it can 
be a good marker of significant fibrosis if the sample size 
is large enough, just as was found in the study by Zhou 
et al (12). The models that correlated best with histologi-
cal scores were LSM, S index, and GPRI. However, Fibro-Q 
(P = 0.066) could also have significantly correlated with fi-
brosis stage if the sample size had been larger or distri-
bution of patients in different fibrosis stages more even. 
Further analysis revealed that LSM values correlated more 
strongly with S index and GPRI than with other models. Fi-
nally, our findings indicated that S index and GPRI were the 
best models for diagnosing significant liver fibrosis. Cast-
era et al (24) demonstrated that combinations of LSM and 
other serum fibrosis models could avoid the need for liver 
biopsy in more than two thirds of patients with CHB. In our 
study, combinations of S index plus LSM or GPRI plus LSM 
better predicted significant fibrosis than either S index or 
FIGURe 1. Receiver operating characteristic curves of serum models for 
predicting significant liver fibrosis. serum liver fibrosis models, including 
age-platelet (PLt) index (aPI), aspartate transaminase (ast) to alanine 
aminotransferase (aLt) ratio (aaR), ast to PLt ratio index (aPRI), γ-glutamyl 
transpeptidase (GGt) to PLt ratio index (GPRI), GGt-PLt-albumin index (s 
index), age-ast-PLt-aLt index (FIB-4), and age-ast-PLt-aLt-international 
normalized ratio index (Fibro-Q) showed different results in diagnosing 
significant liver fibrosis in patients with chronic hepatitis B. Judging from 
the area under the receiver operating characteristic curves, s index and 
GPRI had the best diagnostic value, followed by FIB-4, aPRI, aPI, Fibro-Q, 
and aaR.
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GPRI alone. One explanation is that combinations of LSM 
(a model with a low false-positive result) with GPRI or S in-
dex (models with high false-negative results) were able to 
reduce the incidence of both false negative and false-pos-
itive results, thus improving diagnostic performance. Diag-
nostic sensitivity of the combined models was more than 
20% better than LSM alone, even though the AUROCs did 
not improve.
The S index includes GGT, PLT, and ALB, whereas GPRI 
only includes GGT and PLT. These scores can differentiate 
liver fibrosis and can be simply calculated by straightfor-
ward formulas. Serum ALB and GGT concentrations and 
PLT count differ significantly between patients with F0-
F1 and those with F2-F4 liver fibrosis. With progression 
of fibrosis, the decreased ability of hepatocytes to syn-
thesize ALB leads to a decrease in serum ALB concentra-
tions, which is why serum ALB can serve as an indirect 
indicator of liver fibrosis. Serum GGT, on the other hand, 
can be an independent predictive marker of liver fibrosis, 
since it is not affected by changes in ALT or TBIL (25). The 
splenic platelet pool may be greatly increased in the pres-
ence of splenomegaly, since up to 50%-90% of platelets 
are sequestered in the spleen. This redistribution of cells 
from the peripheral circulation to the spleen can result in 
thrombocytopenia (26). On the other hand, as liver dis-
ease progresses from inflammation to fibrosis and finally 
to cirrhosis, decreased production of thrombopoietin as-
sociated with hepatocellular damage may contribute to 
exacerbation of thrombocytopenia (27). In addition, anti-
body-mediated platelet destruction (28) and myelotoxic 
effects (29) can also cause decreased platelet counts.
APRI, FIB-4, AAR, and Fibro-Q contain several inflammatory 
biomarkers, including AST or ALT. Fluctuating patterns of 
AST or ALT may limit the applicability of these models in 
patients with CHB, which is not the case in patients with 
CHC (30,31). API was first implemented in patients with 
CHC and one of its two variables is age, which in our study 
did not correlate with liver fibrosis stage. This may explain 
why in our study AUROC for API was lower than in other 
reports (32,33).
In conclusion, we found that S index and GPRI were the 
simple and most useful of the seven models for prediction 
of significant liver fibrosis in patients with CHB, which is 
of particular importance in the settings where FibroScan 
is unavailable. Combining LSM and either S index or GPRI 
seems a promising approach that may increase the perfor-
mance for diagnosis of significant liver fibrosis.
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